• Wednesday, June 05, 2024
    Hives, asthma, or eczema - they're all very common symptoms of an allergic reaction[1]. When mild, allergies cause irritation and discomfort, yet when severe, they can result in anaphylaxis and even death.Now, health experts at the University of South Australia[2] are calling for a renewed focus on allergy training for nurses to deliver allergy treatments, source reliable evidence-based resources and provide patient education to patients and their families across the health sector.It's a timely move ahead of World Allergy Week[3] (23-29 June).Currently, allergic disease affects more than four million Australians[4], with numbers expected to almost double[5] in the next 20 ...
  • Wednesday, June 05, 2024
    At the Allergy, Asthma & Sinus Center in Greenfield, staff members collect daily pollen samples to monitor the pollen count in the air we all breathe."Every day someone in the office makes a new slide. So we have to take out the old one, which has all of the collections on it," said Jenna Lewis, a member from the Allergy, Asthma & Sinus Center, who explained the daily routine.This process helps them identify and count microscopic pollen grains. Rene Steven provides insight into the types of pollen currently prominent."This is actually a photo micrograph of grass pollen. This is one ...
  • Saturday, March 09, 2024
    Star Health Desk Sun Mar 10, 2024 12:00 AM Last update on: Sun Mar 10, 2024 12:57 AM Omalizumab is a new drug that the FDA recently approved to help treat food allergies, especially peanut allergies, in the United States. This medication is given as a shot and works by targeting a specific part of the immune system involved in allergic reactions. In a study published in the New England Journal of Medicine, researchers found that children and adolescents with peanut allergies who took omalizumab were better able to tolerate peanuts compared to those who did not take the medication.After ...
  • Friday, March 01, 2024
    In a landmark decision that promises to transform the lives of millions afflicted with food allergies, the U.S. Food and Drug Administration (FDA) has approved Xolair, an injectable medication previously designated for asthma treatment, now repurposed to safeguard against severe allergic reactions to foods. This approval stems from groundbreaking research indicating Xolair's efficacy in dulling the body's overzealous immune responses to common allergens like peanuts, milk, and eggs, offering a beacon of hope to those navigating the perilous waters of food allergies. A Milestone in Allergy Treatment The recent FDA approval[1] marks a significant departure from conventional allergy management strategies, ...
  • Thursday, February 22, 2024
    How to prepare now for spring allergies  TODAY
  • Wednesday, February 14, 2024
    As spring approaches, so too does the inevitable allergy[1] symptom surge that many end up experiencing. As allergy season appears on the horizon, it becomes clear that the impacts of sinus conditions such as chronic rhinosinusitis may only be made worse and may also require diagnosis and treatment sooner rather than later.Chronic rhinosinusitis is an inflammatory condition that is seen in the paranasal sinuses, and it is characterized by its persistence for over 12 weeks. The condition is known to impact around 5% of the population in the US.1Though the association between allergies and chronic rhinosinusitis remains opaque, variants of ...
  • Thursday, February 08, 2024
    Allergies occur when your body's defense system (immune system) overreacts to certain substances. In these cases, the immune system treats a harmless substance as if it were a harmful germ or virus. Many things can cause this to happen. Understanding seasonal allergiesYour allergies[1] are seasonal if you have symptoms just at certain times of the year. In that case, you are probably allergic to pollens from certain trees, grasses or weeds.Allergies can be mild or severe. Over-the-counter allergy medicines[2], such as nasal sprays, eye drops or pills, may help with some symptoms[3]. Read and follow all instructions on the label.Your doctor[4] ...
  • Monday, February 05, 2024
    Company LogoGlobal Allergy Immunotherapy MarketGlobal Allergy Immunotherapy MarketDublin, Feb. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Allergy Immunotherapy Market (2023-2028) by Type, Application and Distribution Channel, and Geography, Competitive Analysis, Impact of Covid-19, Ansoff Analysis"[1] report has been added to ResearchAndMarkets.com's offering.The Allergy Immunotherapy Market is undergoing significant growth and transformation, with the latest industry analysis projecting its value to reach USD 2.69 billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 8.12%. This market's expansion is driven by increased awareness of allergy treatment options and advances in immunotherapy practices. The analysis offers in-depth insights that cater ...
  • Friday, January 12, 2024
    Why have I been blocked? This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.
  • Friday, January 05, 2024
    SpecialtyPlease chooseI'm not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI'm not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous
  • Thursday, January 04, 2024
    Share on Pinterest[1]Researchers say the rare food allergy eosinophilic esophagitis is more prevalent among non-white children than previously thought. FatCamera/Getty ImagesIn the largest-ever study of pediatric allergies, researchers from the Children’s Hospital of Philadelphia analyzed electronic health records from more than 200,000 children.The researchers reported that eosinophilic esophagitis (EoE), a rare food allergy previously associated with white males, is more common among non-white people than previously believed.They say this research underscores the significant impact of allergic conditions on children’s well-being and emphasizes the need for a precise understanding of their prevalence and risk factors, while also highlighting the importance of ...
  • Wednesday, December 27, 2023
    SILVER SPRINGS, MD.-A drug that has already been approved for asthma and hives may protect people with food allergies from reactions to peanuts, eggs, milk and other foods.According to an NBC News report[1], a clinical trial testing the injectable drug Xolair in 165 children and adolescents backed by the National Institute of Allergy and Infectious Diseases[2] found that those treated with the drug were able to eat more of the foods without suffering a reaction.The Food and Drug Administration[3] announced that it is fast-tracking Xolair to be used against accidental exposure to foods, however, for the drug to get full ...
  • Wednesday, December 20, 2023
    If approved, monoclonal antibody omalizumab would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure.The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental Biologics License Application for Xolair® (omalizumab) for treatment of children and adults with food allergies.The drug, a monoclonal antibody, could be used in adults and children over 1 year of age for reduction of allergic reactions, including anaphylaxis, that may occur following accidental exposure to one or more foods.“Despite the significant and growing health burden from food allergies, treatment advances have been limited,” said Levi Garraway, ...

Nashville ENT & Allergy

4230 Harding Road, Suite 400
Nashville,  TN 37205
Phone: (615) 386-9089